scholarly journals Early success transplanting kidneys from donors with new SARS‐CoV‐2 RNA positivity: A report of 10 cases

Author(s):  
Christine E Koval ◽  
Emilio D Poggio ◽  
Yi‐Chia Lin ◽  
Hannah Kerr ◽  
Mohamed Eltemamy ◽  
...  
Keyword(s):  
Antibodies ◽  
2021 ◽  
Vol 10 (3) ◽  
pp. 30
Author(s):  
Andrew T. Lucas ◽  
Amber Moody ◽  
Allison N. Schorzman ◽  
William C. Zamboni

Antibody-drug conjugates (ADCs) appear to be in a developmental boom, with five FDA approvals in the last two years and a projected market value of over $4 billion by 2024. Major advancements in the engineering of these novel cytotoxic drug carriers have provided a few early success stories. Although the use of these immunoconjugate agents are still in their infancy, valuable lessons in the engineering of these agents have been learned from both preclinical and clinical failures. It is essential to appreciate how the various mechanisms used to engineer changes in ADCs can alter the complex pharmacology of these agents and allow the ADCs to navigate the modern-day therapeutic challenges within oncology. This review provides a global overview of ADC characteristics which can be engineered to alter the interaction with the immune system, pharmacokinetic and pharmacodynamic profiles, and therapeutic index of ADCs. In addition, this review will highlight some of the engineering approaches being explored in the creation of the next generation of ADCs.


2018 ◽  
Vol 37 (3) ◽  
pp. 386-393 ◽  
Author(s):  
K. John McConnell ◽  
Christina J. Charlesworth ◽  
Thomas H. A. Meath ◽  
Rani M. George ◽  
Hyunjee Kim

Urology ◽  
2004 ◽  
Vol 63 (1) ◽  
pp. 110-113 ◽  
Author(s):  
Chandrika Patel ◽  
Mohamed A. Elshaikh ◽  
Kenneth Angermeier ◽  
James Ulchaker ◽  
Eric A. Klein ◽  
...  
Keyword(s):  

Science ◽  
2021 ◽  
Vol 372 (6541) ◽  
pp. 448-448
Author(s):  
Meredith Wadman

Author(s):  
Mark Stout ◽  
Jang Woo Park ◽  
Ali Dogan ◽  
Ricardo Teixeira

Erard ◽  
2021 ◽  
pp. 88-103
Author(s):  
Robert Adelson

The Erards realised that as brilliant as the double-escapement action was, it required an equally brilliant pianist to introduce it to the public. The Erards first thought to ask the Austrian pianist and composer Johann Nepomuk Hummel (1778–1837), but soon found another pianist to promote their invention: a musician whose talents eclipsed not only those of Morel, but also those of all other living pianists. Franz Liszt (1811–86), then only twelve years old and largely unknown outside of Vienna, arrived in Paris and became the leading advocate for Erard’s new invention. Liszt’s relationship with the Erard family quickly became advantageous to both parties. For the Erards, Liszt’s arrival was a godsend, as his superhuman technique demonstrated the advantages of their invention. Similarly, Erard’s new piano became an essential part of Liszt’s early success, as its magnificently responsive action and powerful tone allowed the pianist to push his virtuosity to new heights.


Sign in / Sign up

Export Citation Format

Share Document